Malvern, PA-based TetraLogic has added $5 million to a previously announced $32 million Series C, bringing the developer's total haul for this round to $37 million. Pfizer Ventures added the extra cash, joining a syndicate of investors led by Clarus Ventures.
TetraLogic has been gathering funding to support the development of early-stage cancer drug TL32711, a SMAC mimetic designed to neutralize the activity of an inhibitor of apoptosis proteins, which block tumor cell death. It's under investigation as a single agent in patients with hard-to-treat solid tumors and lymphoma.
"This investment is part of Pfizer Ventures' overall strategy to finance emerging companies discovering and developing promising treatments for unmet medical needs, so we're very pleased to join TetraLogic and its investors to support its efforts to advance SMAC mimetics as potential new treatments for cancer," says Elaine Jones, executive director of Pfizer Ventures.
- check out the release from TetraLogic